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Chronic lymphocytic leukemia (CLL) is the most 
common human leukemia, accounting for  ~10,000 
new cases diagnosed each year in the United States 
(~30% of all leukemia cases) [1]. CLL is mostly a 
disease of elderly people, with the incidence increasing 
linearly with each decade [1,2]. This disease occurs in 
two forms, aggressive and indolent, both forms are is 
characterized by the clonal expansion of CD5 positive 
B-cells [1,2]. Aggressive CLL is characterized by high 
ZAP-70 expression and unmutated IgH VH; indolent 
CLL shows low ZAP-70 expression and mutated IgH 
VH [1,2]. 
MicroRNAs are endogenous non-coding RNAs 19-
25 nucleotides in size [3]. Recent studies have shown 
that microRNAs play important roles in  various 
cellular processes including DNA methylation [4], 
cellular growth, differentiation and apoptosis [5]. 
Recent studies revealed that nearly half of human 
microRNAs are located within fragile sites and 
genomic regions altered in various cancers [6]. 
Numerous reports demonstrated that, as protein coding 
genes, microRNAs differentially express in a number 
of cancers, indicating that individual microRNAs could 
play tumor suppressor or oncogenenic roles in cancer 
pathogenesis [7]. 
Several recent studies demonstrated that microRNA 
expression profiles can be used to distinguish normal 
B-cells from malignant CLL cells and that microRNA 
signatures are associated with prognosis and 
progression of CLL [6,8]. Specifically, a signature 
profile was reported, describing 13 microRNAs that 
differentiate aggressive and indolent CLL [6].  
Tcl1 is a critical molecule in the pathogenesis of 
CLL [9]. Mouse model studies conclusively 
demonstrated that deregulation of TCL1 is initiating 
event in the development of the aggressive form of 
CLL [10,11], in fact recent studies showed that Tcl1-
driven mouse CLL closely resembles the aggressive 
form of human B-CLL and the analysis for VH 
mutations showed that all the CLLs in transgenic mice 
carried unmutated VH genes in accordance with the 
aggressive phenotype [12]. We, and others, reported 
that the aggressive form of human B-CLL shows the 
highest Tcl1 expression levels  [13,14]. Several years 
ago we investigated whether microRNAs regulate 
TCL1 expression in CLL. We demonstrated that miR-
29 and miR-181 target TCL1 expression in CLL [14]. 
Interestingly, of the four down-regulated microRNAs 
in aggressive CLL versus indolent B-CLL, three are 
different isoforms of miR-29 (miR-29a-2, miR-29b-2 
and miR-29c) [6], strongly suggesting that miR-29 and 
TCL1 interactions play an important role in the 
pathogenesis of aggressive CLL [14]. The fact that 
miR-29 targets expression of TCL1, a critical oncogene 
in aggressive CLL, indicates that miR-29 might 
function as a tumor suppressor in CLL. 
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ABSTRACT: 
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is 
characterized by high ZAP-70 expression and unmutated IgH VH; indolent CLL shows 
low ZAP-70 expression and mutated IgH VH. We recently found that miR-29 is up-
regulated in indolent human B-CLL, compared to aggressive B-CLL and normal CD19
+ 
B-cells. To determine the role of miR-29 in CLL, we generated transgenic mice over-
expressing  miR-29 in mouse B-cells. Recently we reported that miR-29 transgenic 
mice develop indolent CLL phenotype. Interestingly, our previous findings suggest 
that  miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, 
indicating that miR-29 might function as a tumor suppressor in CLL.  Here we discuss 
these results and provide additional insights into function of miR-29 in CLL.  
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As noted above, we have previously reported that 
miR-29 expression is down-regulated in aggressive 
versus indolent CLL [8,14], but these reports did not 
examine  miR-29 expression in CLL versus normal 
CD19+ B-cells. In our latest publication in PNAS we 
examined expression of miR-29a and miR-29b in 29 
aggressive CLL samples, 33 indolent CLL samples and 
two normal CD19+ B-cell controls [15]. We found that 
miR-29a and miR-29b expression was 4-4.5 fold 
higher in indolent CLL, when compared with normal 
CD19+ B-cells [15].  Table 1 shows summary of miR-
29 expression in CLL from three studies. Deletion of 
chromosome 11 in CLL usually indicates most 
aggressive phenotype. Interestingly, CLL samples 
showing this particular deletion express lowest levels 
of  miR-29. These data clearly indicate that miR-29a 
and miR-29b expression is clearly down-regulated in 
aggressive CLL versus indolent CLL. 
Although deregulation of a specific gene in a 
certain type of cancer suggests a potential involvement 
in the malignancy, the final proof of the involvement of 
this gene in the pathogenesis of this disease requires 
generation of animal models showing the same 
malignant phenotype. To elucidate the role of miR-29 
in B-cell leukemias we generated transgenic mice over-
expressing  miR-29 in B-cells. Very recently we 
reported the phenotype of this mouse model [15]. 
Immunophenotypic profile of spleen lymphocytes 
from miR-29 transgenics showed increased populations 
of CD5+CD19+IgM+ B-cells, a characteristic of CLL. 
At the age of 12-24 months markedly expanded CD5
+ 
B-cell population was evident in spleens of 34 of 40 
(85%) miR-29 transgenic mice; ~50% of B-cells in 
these transgenics were CD5 positive [15]. Interestingly, 
of 20 miR-29 transgenic mice followed to 24-26 
months of age, only 4 (20%) developed frank leukemia 
and died of the disease. Because almost all miR-29 
transgenics showed expanded CD5+CD19+IgM+ B-
cell populations, but only 20% develop frank leukemia 
we concluded that miR-29 transgenics develop a 
disease similar to indolent CLL [15]. In addition, miR-
29 mice showed significant increases in % of leukemic 
cells with age.  In mice younger than 15 months, CD5+ 
leukemic cells represented only ~20% of total B-cells; 
in contrast, at the age of 20-26 months, on average, 
>65% of all B-cells were CD5+. These results show 
gradual progression of indolent B-CLL in miR-29 
transgenics [15]. To determine whether leukemic cells 
from  miR-29 mice divide, we measured the 
proliferative capacity of CD5+ leukemic B-cells in 
comparison with WT CD19+ splenic lymphocytes.   
BrdU incorporation experiments showed significant 
proliferation in miR-29 transgenic B-cells, while no 
proliferation was detected for CD19+ WT lymphocytes 
[15].  These data suggest that miR-29 over-expression 
plays an important role in promoting B-cell 
proliferation.  Since progressive hypogammaglobulinemia 
and immune incompetence are important features of 
human CLL [16], we analyzed serum levels of 
immunoglobulins and the immune response to SRBC 
antigen in the serum of miR-29 transgenics and wild 
type siblings. We found that in miR-29 transgenics 
immune response to SRBC antigen and serum levels of 
immunoglobulins were significantly decreased [15]. 
Table 1 Mir-29 expression in CLL 
Study 
ref.  Number of samples  Method  Results 
[8] 
Aggressive CLL                        36
Indolent CLL                             47 
Microchip
 
miR-29a and  miR-29b down-regulated in 
aggressive CLL vs.indolent CLL 
[14] 
Aggressive CLL                        25
Aggr. CLL (Del. Chr. 11)          32 
Indolent CLL                             23 
Microchip miR-29a and  miR-29b down-regulated in 
aggressive CLL (Del. Chr 11) vs.indolent CLL 
(~2 fold) 
miR-29b down-regulated in aggressive CLL vs. 
indolent CLL (~ 2 fold) 
[15] 
Aggressive CLL                        29
Indolent CLL                             33 
Normal cord blood B-cells          2 
Real Time
RT-PCR 
miR-29a down-regulated in aggressive CLL vs. 
indolent CLL (~ 1.5 fold) 
miR-29a and miR-29b up-regulated in aggressive 
CLL vs. normal B-cells (~ 3 fold) 
miR-29a and miR-29b up-regulated in indolent 
CLL vs. normal B-cells (~ 4-5 fold) 
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Fig. 1 Role of miR-29 in CLL. 
These data confirmed our initial observations that miR-
29 transgenic mice develop disease that mimics 
indolent human CLL.  
Previously we reported that miR-29 is one of two 
microRNAs targeting TCL1, a very important 
oncogene involved in the pathogenesis of aggressive 
CLL [14]. We also showed that TCL1 and miR-29 
expression levels are inversely correlated in CLL, and 
that miR-29 expression is down-regulated in aggressive 
CLL  versus indolent CLL [14].  These data suggest 
possible tumor suppressor function for miR-29 in CLL. 
Very recently we reported that miR-29 is up-regulated 
in indolent CLL compared to normal B-cells [15]. We 
also found that miR-29 transgenic mice showed 
expanded CD5+CD19+IgM+ B-cell populations and 
develop a disease very similar to indolent human CLL 
[15]. This implies that up-regulation of miR-29 
initiates or at least significantly contributes to the 
pathogenesis of indolent CLL and can function as an 
oncogene. How can we reconcile these differences? 
Figure 1 shows our current view of the function of 
miR-29 in CLL. Since TCL1 is mostly not expressed in 
indolent CLL [14], it likely does not play an important 
role in indolent CLL. Thus its down-regulation due to 
miR-29 overexpression does not slow indolent CLL 
development. We believe that up-regulation of miR-29 
expression is not sufficient to cause aggressive CLL. In 
contrast, up-regulation of Tcl1 is absolutely required 
for the initiation of the aggressive form of CLL. In the 
other hand, down-regulation of miR-29 expression in 
aggressive CLL (compared to the indolent form) 
contributes to up-regulation of Tcl1 and development 
of aggressive CLL. 
Since in all human B-CLL samples miR-29a 
expression levels were >20-fold higher compared to 
miR-29b [15]  and both microRNAs share the same 
seed sequence, it is likely that most of effects of 
expression of miR-29ab  cluster in CLL can be 
attributed to miR-29a.  MiR-29 functions as an 
oncogene in B-cells by regulating its targets. 
Targetscan software predicts over 800 targets for miR-
29. This list contains multiple oncogenes and tumor 
suppressor genes. Previous reports showed that miR-29 
can target TCL1,  MCL1 and CDK6 oncogenes 
[14,17,18]; we propose that miR-29 targets possible 
tumor suppressor peroxidasin [15]. Clearly, 
interactions of miR-29 with these genes contribute to 
its function, but it is very likely that hundreds of 
unknown interactions of miR-29 with its targets hold 
keys to its oncogenic role in CLL. 
MicroRNA expression profiles were extensively 
studied in a number of hematological malignancies as 
well as in solid tumors [7]. These studies resulted in 
identification of several microRNAs that might 
function as tumor suppressors or oncogenes [7]. 
However, there have been only two reports 
demonstrating that dysregulation of a single microRNA 
(or a cluster) can cause cancer. The first such study 
defined an initiation role of miR-155 in B-cell acute 
leukemias [19]. Another study demonstrated that 
knockout of miR-15/16 led to the development of 
indolent B-cell malignancies [20,21]. In both cases 
previously published reports identified miR-155 as an 
oncogene and miR-15/16 as a tumor suppressor. In 
contrast, there has not been a clear consensus regarding 
the function of miR-29 in this respect. Previous studies 
showed that miR-29 expression was down-regulated 
and correlated with poor prognosis in mantle cell 
lymphoma [22], its re-expression caused apoptosis 
AML cells [17] and suppressed tumorigenicity in lung 
cancer cells [23].  On the other hand, in addition to our 
report [15], dysregulation of miR-29 expression in 
myeloid cells was found to cause AML in a mouse 
model [24], and its overexpression was reported in 
metastatic breast cancer [25]. Thus, it is apparent that 
depending on cellular contexts miR-29 can function as 
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